Promedior's new $21.5M series D helps advance fibrosis portfolio, including IPF and mylelofibrosis
This article was originally published in Scrip
Executive Summary
Promedior, a US company developing therapies for fibroproliferative diseases, has novel biologic candidates in some crowded investigational areas, but it believes its candidates offer a highly differentiated approach – and it hopes to have proof of concept data next year. The company has just gained a fresh $21.5 million injection of venture cash in a series D financing round, led by a new investor, Fibrotec Ventures LLC (which focuses on innovative fibrosis platforms).